{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:07:29Z","timestamp":1792098449597,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ccell.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T10:32:53Z","timestamp":1557743573000},"page":"738-751.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":257,"title":["Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants"],"prefix":"10.1016","volume":"35","author":[{"given":"Bryan D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia B.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Rutkoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Mi","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gada","family":"Al-Ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie L.","family":"Bulfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Ensinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly M.","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arin","family":"McKinley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Patt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanumaiah","family":"Telikepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajia","family":"Town","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshminarayana","family":"Vogeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha","family":"Vogeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni Ryan","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2019.04.006_bib1","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2010.07.134","article-title":"Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region","volume":"20","author":"Ahn","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ccell.2019.04.006_bib2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2019.04.006_bib3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of\u00a0the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2019.04.006_bib4","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","article-title":"Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor","volume":"66","author":"Bauer","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2019.04.006_bib5","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2019.04.006_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.ccell.2019.04.006_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ctrv.2010.11.003","article-title":"A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST","volume":"37","author":"Blay","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ccell.2019.04.006_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2019.04.006_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2019.04.006_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2019.04.006_bib11","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","article-title":"Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T\u00a0cell activation and to promote regulatory T\u00a0cell expansion","volume":"186","author":"Coffelt","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ccell.2019.04.006_bib12","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2019.04.006_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2019.04.006_bib14","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2019.04.006_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2019.04.006_bib16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2019.04.006_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jb\/mvq015","article-title":"Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance","volume":"147","author":"DiNitto","year":"2010","journal-title":"J.\u00a0Biochem."},{"key":"10.1016\/j.ccell.2019.04.006_bib18","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1038\/sj.onc.1207525","article-title":"Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)","volume":"23","author":"Duensing","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2019.04.006_bib58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.ccell.2019.04.006_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2019.04.006_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2019.04.006_bib21","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1016\/S0021-9258(19)49853-0","article-title":"Angiogenesis","volume":"267","author":"Folkman","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2019.04.006_bib22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1073\/pnas.0812413106","article-title":"KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients","volume":"106","author":"Gajiwala","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2019.04.006_bib23","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","article-title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in\u00a0heavily pretreated gastrointestinal stromal tumor (GIST) patients","volume":"20","author":"Garner","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2019.04.006_bib24","doi-asserted-by":"crossref","first-page":"11511","DOI":"10.1200\/JCO.2018.36.15_suppl.11511","article-title":"Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618","volume":"36","author":"George","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2019.04.006_bib25","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ccell.2019.04.006_bib26","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s00280-010-1526-3","article-title":"Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor","volume":"67","author":"Gounder","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ccell.2019.04.006_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2019.04.006_bib28","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-17-0241","article-title":"The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2Hi macrophages in breast cancer and pancreatic neuroendocrine tumors","volume":"16","author":"Harney","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ccell.2019.04.006_bib29","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2019.04.006_bib30","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2019.04.006_bib31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ccell.2019.04.006_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ccell.2019.04.006_bib33","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2019.04.006_bib34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/MCB.00943-14","article-title":"Kinase regulation by hydrophobic spine assembly in cancer","volume":"35","author":"Hu","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ccell.2019.04.006_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2019.04.006_bib36","doi-asserted-by":"crossref","first-page":"mdx387","DOI":"10.1093\/annonc\/mdx387","article-title":"Encouraging activity of novel pan-KIT and PDGFR\u03b1 inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST)","volume":"28","author":"Janku","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2019.04.006_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1823","article-title":"Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme","volume":"207","author":"Joensuu","year":"2005","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ccell.2019.04.006_bib38","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2019.04.006_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccr.2005.05.024","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"7","author":"Joyce","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2019.04.006_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0002-9440(10)63120-3","article-title":"KIT mutations are common in testicular seminomas","volume":"164","author":"Kemmer","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ccell.2019.04.006_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2018.06.016","article-title":"Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases","volume":"191","author":"Klug","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ccell.2019.04.006_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.13560","article-title":"Concurrent activating KIT mutations in systemic mastocytosis","volume":"173","author":"Lasho","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ccell.2019.04.006_bib59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1107\/S090744491200251X","article-title":"JLigand: a graphical tool for the CCP4 template-restraint library","volume":"68","author":"Lebedev","year":"2012","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.ccell.2019.04.006_bib43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","article-title":"Heterogeneity of kinase inhibitor resistance mechanisms in GIST","volume":"216","author":"Liegl","year":"2008","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ccell.2019.04.006_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11899-009-0011-8","article-title":"Clinical implications of c-Kit mutations in acute myelogenous leukemia","volume":"4","author":"Malaise","year":"2009","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ccell.2019.04.006_bib60","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr"},{"key":"10.1016\/j.ccell.2019.04.006_bib45","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.0511292103","article-title":"An efficient rapid system for profiling the cellular activities of molecular libraries","volume":"103","author":"Melnick","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2019.04.006_bib46","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase","volume":"279","author":"Mol","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2019.04.006_bib61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"10.1016\/j.ccell.2019.04.006_bib47","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ccell.2019.04.006_bib48","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","article-title":"Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study","volume":"24","author":"Paschka","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2019.04.006_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2019.04.006_bib50","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.4161\/cbt.8.21.9764","article-title":"Amplification of chromosomal segment 4q12 in non-small cell lung cancer","volume":"8","author":"Ramos","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ccell.2019.04.006_bib51","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2019.04.006_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1758834014522491","article-title":"Recent advances in the treatment of gastrointestinal stromal tumors","volume":"6","author":"Serrano","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ccell.2019.04.006_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2567.2003.01559.x","article-title":"Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene","volume":"108","author":"Sundstrom","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.ccell.2019.04.006_bib54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2019.04.006_bib55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ccell.2019.04.006_bib56","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chembiol.2010.09.010","article-title":"Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry","volume":"17","author":"Wodicka","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ccell.2019.04.006_bib57","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-06-1823","article-title":"Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors","volume":"67","author":"Wyckoff","year":"2007","journal-title":"Cancer Res."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610819302016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610819302016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:01:10Z","timestamp":1761523270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610819302016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1535610819302016"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2019.04.006","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}